Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it
remains unclear how these proteins interact to promote disease. Here, by combining cross …

In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …

Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that
tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (A β). We …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …